Melinda L. Telli, M.D.

Publications

• Underestimating cardiac toxicity in cancer trials: lessons learned? Witteles RM, Telli M. J Clin Oncol. 2012; 30 (16): 1916-8
• Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Telli ML, Chang ET, Kurian AW, Keegan TH, McClure LA, Lichtensztajn D, Ford JM, Gomez SL. Breast Cancer Res Treat. 2011; 127 (2): 471-8
• PARP inhibitors in cancer: moving beyond BRCA. Telli ML, Lancet Oncol. 2011; 12 (9): 827-8
• Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM. J Am Coll Cardiol. 2010; 56 (20): 1644-50
• Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Telli ML, Witteles RM, Fisher GA, Srinivas S. Ann Oncol. 2008; 19 (9): 1613-8
• Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. Telli ML, Hunt SA, Carlson RW, Guardino AE. J Clin Oncol. 2007; 25 (23): 3525-33
• Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN, Balmana J, Gruber SB, Ford JM, Euhus D, Lebensohn A, Telli M, Pochebit SM, Lypas G, Garber JE. Breast Cancer Res Treat. 2012; 133 (3): 1125-30
• Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome. Henry E, Villalobos V, Million L, Jensen KC, West R, Ganjoo K, Lebensohn A, Ford JM, Telli ML. J Natl Compr Canc Netw. 2012; 10 (8): 939-42
• Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Palesh O, Peppone L, Innominato PF, Janelsins M, Jeong M, Sprod L, Savard J, Rotatori M, Kesler S, Telli M, Mustian K. Nat Sci Sleep. 2012: 4 151-162
• Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA, Sheth S, Kurian AW, Ford JM, Stockdale FE, Quake SR, Pease RF, Mindrinos MN, Bhanot G, Dairkee SH, Davis RW, Jeffrey SS. PLoS One. 2012; 7 (5): e33788
• Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented? Witteles RM, Fowler MB, Telli ML. Heart Fail Clin. 2011; 7 (3): 333-44
• Trastuzumab-related cardiac dysfunction. Telli ML, Witteles RM. J Natl Compr Canc Netw. 2011; 9 (2): 243-9
• Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California. Gomez SL, Lichtensztajn D, Kurian AW, Telli ML, Chang ET, Keegan TH, Glaser SL, Clarke CA. J Clin Oncol. 2010; 28 (10): e155-7; author reply e158
• Longer relative telomere length in blood from women with sporadic and familial breast cancer compared with healthy controls. Gramatges MM, Telli ML, Balise R, Ford JM. Cancer Epidemiol Biomarkers Prev. 2010; 19 (2): 605-13
• Novel treatment approaches for triple-negative breast cancer. Telli ML, Ford JM. Clin Breast Cancer. 2010: 10 Suppl 1 E16-22
• PARP inhibitors in breast cancer. Telli ML, Ford JM. Clin Adv Hematol Oncol. 2010; 8 (9): 629-35
• First-line chemotherapy for metastatic breast cancer. Telli ML, Carlson RW. Clin Breast Cancer. 2009: 9 Suppl 2 S66-72
• Phyllodes tumors of the breast: natural history, diagnosis, and treatment. Telli ML, Horst KC, Guardino AE, Dirbas FM, Carlson RW. J Natl Compr Canc Netw. 2007; 5 (3): 324-30
• Epidermal growth factor and angiotensin II regulation of extracellular signal-regulated protein kinase in rat liver epithelial WB cells. Yang LJ, Guo YL, Trygankova O, Li QY, Maloney JA, Steinhauer M, Williamson JR. Biochem Pharmacol. 1999; 57 (4): 425-32